Sökning: WFRF:(Kueng W) > Pooled analysis of ...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 05213naa a2200757 4500 | |
001 | oai:lup.lub.lu.se:3d865be1-5a19-40bc-b816-c9d1922c96f3 | |
003 | SwePub | |
008 | 160401s2002 | |||||||||||000 ||eng| | |
024 | 7 | a https://lup.lub.lu.se/record/3457802 URI |
024 | 7 | a https://doi.org/10.1093/jnci/94.2.1162 DOI |
040 | a (SwePub)lu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a art2 swepub-publicationtype |
072 | 7 | a ref2 swepub-contenttype |
100 | 1 | a Look, MP4 aut |
245 | 1 0 | a Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 8377 breast cancer patients |
264 | 1 | b Oxford University Press (OUP),c 2002 |
520 | a Background: Urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) play essential roles in tumor invasion and metastasis. High levels of both uPA and PAT-1 are associated with poor prognosis in breast cancer patients. To confirm the prognostic value of uPA and PAI-1 in primary breast cancer, we reanalyzed individual patient data provided by members of the European Organization for Research and Treatment of Cancer-Receptor and Biomarker Group (EORTC-RBG). Methods: The study included 18 datasets involving 8377 breast cancer patients. During follow-up (median 79 months), 35% of the patients relapsed and 27% died. Levels of uPA and PAI-1 in tumor tissue extracts were determined by different immunoassays; values were ranked within each dataset and divided by the number of patients in that dataset to produce fractional ranks that could be compared directly across datasets. Associations of ranks of uPA and PAI-1 levels with relapse-free survival (RFS) and overall survival (OS) were analyzed by Cox multivariable regression analysis stratified by dataset, including the following traditional prognostic variables: age, menopausal status, lymph node status, tumor size, histologic grade, and steroid hormone-receptor status. All P values were two-sided. Results: Apart from lymph node status, high levels of uPA and PAI-1 were the strongest predictors of both poor RFS and poor OS in the analyses of all patients. Moreover, in both lymph node-positive and lymph nodenegative patients, higher uPA and PAI-1 values were independently associated with poor RFS and poor OS. For (untreated) lymph node-negative patients in particular, uPA and PAI-1 included together showed strong prognostic ability (all P<.001). Conclusions: This pooled analysis of the EORTC-RBG datasets confirmed the strong and independent prognostic value of uPA and PAI-1 in primary breast cancer. For patients with lymph node-negative breast cancer, uPA and PAI-1 measurements in primary tumors may be especially useful for designing individualized treatment strategies. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
700 | 1 | a van Putten, WLJ4 aut |
700 | 1 | a Duffy, MJ4 aut |
700 | 1 | a Harbeck, N4 aut |
700 | 1 | a Christensen, IJ4 aut |
700 | 1 | a Thomssen, C4 aut |
700 | 1 | a Kates, R4 aut |
700 | 1 | a Spyratos, F4 aut |
700 | 1 | a Fernö, Mårtenu Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)onk-mfe |
700 | 1 | a Eppenberger-Castori, S4 aut |
700 | 1 | a Sweep, CGJF4 aut |
700 | 1 | a Ulm, K4 aut |
700 | 1 | a Peyrat, JP4 aut |
700 | 1 | a Martin, PM4 aut |
700 | 1 | a Magdelenat, H4 aut |
700 | 1 | a Brunner, N4 aut |
700 | 1 | a Duggan, C4 aut |
700 | 1 | a Lisboa, BW4 aut |
700 | 1 | a Bendahl, Pär-Olau Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)onk-pbe |
700 | 1 | a Quillien, V4 aut |
700 | 1 | a Daver, A4 aut |
700 | 1 | a Ricolleau, G4 aut |
700 | 1 | a Meijer-van Gelder, E4 aut |
700 | 1 | a Manders, P4 aut |
700 | 1 | a Fiets, WE4 aut |
700 | 1 | a Blankenstein, MA4 aut |
700 | 1 | a Broet, P4 aut |
700 | 1 | a Romain, S4 aut |
700 | 1 | a Daxenbichler, G4 aut |
700 | 1 | a Windbichler, G4 aut |
700 | 1 | a Cufer, T4 aut |
700 | 1 | a Borstnar, S4 aut |
700 | 1 | a Kueng, W4 aut |
700 | 1 | a Beex, LVAM4 aut |
700 | 1 | a Klijn, JGM4 aut |
700 | 1 | a O'Higgins, N4 aut |
700 | 1 | a Eppenberger, U4 aut |
700 | 1 | a Janicke, F4 aut |
700 | 1 | a Schmitt, M4 aut |
700 | 1 | a Foekens, JA4 aut |
710 | 2 | a Bröstcancer-genetikb Sektion I4 org |
773 | 0 | t Journal of the National Cancer Instituted : Oxford University Press (OUP)g 94:2, s. 116-128q 94:2<116-128x 1460-2105x 0027-8874 |
856 | 4 | u http://dx.doi.org/10.1093/jnci/94.2.116x freey FULLTEXT |
856 | 4 | u https://academic.oup.com/jnci/article-pdf/94/2/116/9849235/116.pdf |
856 | 4 8 | u https://lup.lub.lu.se/record/345780 |
856 | 4 8 | u https://doi.org/10.1093/jnci/94.2.116 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy